Stock RLYB RALLYBIO CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Rallybio Corporation

Equities

RLYB

US75120L1008

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
1.77 USD -4.84% Intraday chart for Rallybio Corporation -3.28% -25.94%
May. 15 JPMorgan Downgrades Rallybio to Neutral From Overweight MT
May. 09 Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
JPMorgan Downgrades Rallybio to Neutral From Overweight
MT
Rallybio : The Citizens JMP Life Sciences Conference
PU
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
BU
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
BU
Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting
CI
Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB
AQ
Top Premarket Decliners
MT
US Equity Markets Close Mixed After March Producer Price Inflation Data
MT
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Top Midday Gainers
MT
Wedbush Lowers Rallybio's PT to $11 From $13 After Private Placement, Adjusts Full-Year 2024 Share Count; Maintains Outperform Rating
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report
MT
Top Premarket Gainers
MT
Rallybio Corporation Announces Collaboration with Johnson & Johnson
CI
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
BU
Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.
CI
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
BU
HC Wainwright Cuts Rallybio Price Target to $9 From $12, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLYB Stock
  4. News Rallybio Corporation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW